drugset / Trial / NCT02306694

Prospective Biomarkers of Bone Metabolism in Hemophilia A

NCT02306694

NaSingle-groupOpen-labelTreatment

Summary

One of the major shortcomings in studying bone disease in hemophilia is the lack of fracture outcome data demonstrating the clinical significance of decreased BMD and altered bone biomarkers in the hemophilia population. This study demonstrates that PwH have an increased risk of fracture compared to the general population and that the issue of bone health will increase in importance as the PwH population ages.

Timeline

Start
2014-12
Primary completion
2018-04-16
Completion
2018-04-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ADVATE Protein / enzyme biologic 20 iu/kg